CBLL Earnings

CBLL reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 23.74M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.43 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CBLL's earnings announcement on 2026-02-26, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, CBLL's stock price tends to shift by an average of -0.00% in the 10 days leading up to earnings and -2.26% in the 10 days following, providing insight into potential market.

For , analysts estimate CBLL’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 1.23% and EPS estimates Revise Upward by 1.53% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CBLL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 1.23%, while EPS estimates moved Revise Upward by 1.53% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CBLL's stock price typically moves by -0.00% in the 10 days before its earnings and -2.26% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.